1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Hepatorenal Syndrome Treatment Market, by Type
6.1. Introduction
6.2. Type 1 Hepatorenal Syndrome
6.3. Type 2 Hepatorenal Syndrome

7. Hepatorenal Syndrome Treatment Market, by Treatment
7.1. Introduction
7.2. Surgical Treatment
7.3. Therapeutics

8. Hepatorenal Syndrome Treatment Market, by End-User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Ambulatory Surgical Centers
8.4. Hospitals & Clinics

9. California Hepatorenal Syndrome Treatment Market

10. Florida Hepatorenal Syndrome Treatment Market

11. Illinois Hepatorenal Syndrome Treatment Market

12. New York Hepatorenal Syndrome Treatment Market

13. Ohio Hepatorenal Syndrome Treatment Market

14. Pennsylvania Hepatorenal Syndrome Treatment Market

15. Texas Hepatorenal Syndrome Treatment Market

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. Aetna Inc.
17.2. Baxter International Inc
17.3. Becton, Dickinson and Company
17.4. BioVie Inc
17.5. Cadila Healthcare Limited
17.6. Cumberland Pharmaceuticals Inc
17.7. Edwards Lifesciences Corporation
17.8. F. Hoffmann-La Roche AG
17.9. Fuji Systems Corp
17.10. G Surgiwear Ltd
17.11. GlaxoSmithKline plc
17.12. Johnson & Johnson Co
17.13. La Jolla Pharmaceutical Company
17.14. Lupin Limited
17.15. Mallinckrodt Inc
17.16. Medtronic plc
17.17. Neovii Pharmaceuticals AG
17.18. New Medicon Pharma Lab
17.19. Noorik Biopharmaceuticals AG
17.20. Novartis International AG
17.21. Orphan Therapeutics, LLC
17.22. Pfizer Inc.
17.23. PharmaIN Corporation
17.24. Sanofi S.A.
17.25. Thermo Fisher Scientific

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2027
FIGURE 6. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2020 VS 2027 (%)
FIGURE 11. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2020 VS 2027 (USD MILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2027
FIGURE 13. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2027 (USD MILLION)
FIGURE 16. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2020 VS 2027 (%)
FIGURE 18. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2020 VS 2027 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2027
FIGURE 20. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2027 (USD MILLION)
FIGURE 21. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 22. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2027 (USD MILLION)
FIGURE 23. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 24. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2027 (USD MILLION)
FIGURE 25. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 26. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: FPNV POSITIONING MATRIX
FIGURE 27. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 28. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY STATE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: SCORES
TABLE 14. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: BUSINESS STRATEGY
TABLE 15. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: PRODUCT SATISFACTION
TABLE 16. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: RANKING
TABLE 17. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 18. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: MERGER & ACQUISITION
TABLE 19. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 20. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 21. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: INVESTMENT & FUNDING
TABLE 22. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 23. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

Aetna Inc.
Baxter International Inc
Becton, Dickinson and Company
BioVie Inc
Cadila Healthcare Limited
Cumberland Pharmaceuticals Inc
Edwards Lifesciences Corporation
F. Hoffmann-La Roche AG
Fuji Systems Corp
G Surgiwear Ltd
GlaxoSmithKline plc
Johnson & Johnson Co
La Jolla Pharmaceutical Company
Lupin Limited
Mallinckrodt Inc
Medtronic plc
Neovii Pharmaceuticals AG
New Medicon Pharma Lab
Noorik Biopharmaceuticals AG
Novartis International AG
Orphan Therapeutics, LLC
Pfizer Inc.
PharmaIN Corporation
Sanofi S.A.
Thermo Fisher Scientific